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Abstract The mechanism by which p38 mitogen-activated
protein kinase (MAPK) regulates the induction of cyclooxygen-
ase (COX)-2 by interleukin-1 (IL-1) has been investigated in
HeLa cells. SB 203580, an inhibitor of p38 MAPK, in the range
0.1^1 WM inhibited IL-1-stimulated PGE2 (but not arachidonic
acid) release and this was associated with inhibition of induction
of COX-2 protein and mRNA. IL-1 stimulated COX-2
transcription in HeLa cells about 2-fold as judged by both
reporter gene and nuclear run-on assays. The inhibitor had no
significant effect on this. However, in cells previously stimulated
with IL-1 it caused rapid destabilisation of COX-2 mRNA
independently of on-going transcription. The results suggest a
novel function for p38 MAPK in the regulation of mRNA
stability.
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1. Introduction
p38 mitogen-activated protein (MAP) kinase is strongly ac-
tivated by a number of stimuli including the pro-in£ammatory
cytokines interleukin-1 (IL-1) and tumour necrosis factor K
(TNFK), bacterial lipopolysaccharide and various types of
cellular stress [1,2]. It plays a role in several cellular processes,
including stress-induced cytoskeletal re-organisation [3], plate-
let aggregation [4] and the induction of proteins associated
with the in£ammatory response such as cyclooxygenase
(COX)-2, matrix metalloproteinases, IL-1, IL-6, TNFK, and
inducible nitric oxide synthase [5^7]. These functions are re-
£ected in part by a growing list of proposed downstream
targets of p38 MAPK which include protein kinases such as
MAPK-activated protein kinases 2 and 3 (MAPKAPK-2 and
3) [8] and several transcription factors such as MEF2C [9],
CHOP/GADD153 [10], ATF2 [1], and ternary complex fac-
tors [11].
We have previously shown that SB 203580, a potent pyr-
idinyl imidazole inhibitor of p38 MAPK, strongly inhibited
IL-1-stimulated PGE2 production in human ¢broblasts, and
that this was associated with suppression of induction of
COX-2 mRNA and protein by the cytokine [6]. Similar ¢nd-
ings have been reported for COX-2 induction in IL-1-stimu-
lated mesangial cells [12] and LPS-stimulated monocytes [13].
We also showed that the p38 MAPK inhibitor suppressed
induction by IL-1 of matrix metalloproteinases at the level
of mRNA [6]. This was in contrast to the inhibitor’s e¡ect
on suppression of cytokine production in LPS-stimulated
monocytes which was found to be in large part translational
[14,15].
We have used HeLa cells to study further the role of
p38 MAPK in IL-1-stimulated prostaglandin production
and COX-2 induction. Using SB 203580, we have found
that p38 MAPK activity is essential for stabilising COX-2
mRNA.
2. Materials and methods
2.1. Materials
HeLa cells (human cervical epidermal carcinoma) were from
ECACC, Porton Down, UK. Bacterial plasmids expressing recombi-
nant human GST-c-Jun1ÿ135 and murine His-tagged MAPKAPK-2
were gifts from Dr James Woodgett, Ontario Institute for Cancer
Research, Canada, and Dr Mattias Gaestel, Max-Delbruck Centrum
fuer Molekulare Medizin, Berlin, Germany. Recombinant human
hsp27 was from StressGen. Anti-human COX-2 peptide antiserum
was from Oxford Biomedicals. The rabbit anti-human p38 MAPK
C-terminal peptide antiserum has been described [4]. Sheep anti-hu-
man MAPKAPK-2 antiserum was from Upstate Biotechnology. The
Taq/Pfu mixture ‘TaqPlus Precision’, pBluescript II (KS) and a 1.5-
kb human L-actin cDNA were from Stratagene. The reporter gene
plasmids pCAT3 and pGL3b were from Promega. Human COX-2
cDNA (3.4 kb) was from Professor Desmond Fitzgerald, Royal Col-
lege of Surgeons in Ireland, Dublin, Ireland. A cDNA (1.1 kb) for
human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
from Dr Chris Clark, Kennedy Institute of Rheumatology, London,
UK. Primers CP1 (5P-GCGACGCTATGGTACACAATAGTCACA-
GTACTTTTC-3P) and CP2 (5P-GCGCAAGCTTGTCCTGACGCT-
CACTGC-3P) were from Genosys Biotechnologies. 4-(4-Fluorophen-
yl)-2-(4-methylsulfonylphenyl)-5-(4-pyridinyl) imidazole (SB 203580)
was from Calbiochem. [Q-32P]ATP (3000 Ci/mmol), [K-32P]dCTP
(3000 Ci/mmol), [K-32P]UTP (800 Ci/mmol) and [14C]acetyl coenzyme
A (55 Ci/mmol) were from Amersham Life, [5,6,7,8,11,12,14,15(N)-
3H]arachidonic acid (185 Ci/mmol) was from NEN.
2.2. Cell culture
Adherent HeLa cells were maintained in DMEM/10% (v/v) FCS in
a humidi¢ed atmosphere of 5% (v/v) CO2 at 37‡C. IL-1 stimulation
and other cell treatments were also under these conditions.
2.3. Metabolic labelling of cells with
[5,6,7,8,9,11,12,14,15-3H(N)]arachidonic acid
HeLa cells were grown to approximately 70% con£uence in 12-well
(22 mm diameter) dishes. The medium was removed and replaced with
1 ml DMEM/10% (v/v) FCS containing 0.5 WCi [5,6,7,8,9,11,12,14,15-
3H](N)]arachidonic acid (184.6 Ci/mmol) per ml. Cells were incubated
at 37‡C for 16 h before being washed twice with 1 ml DMEM/FCS.
Either SB 203580 or DMSO vehicle (0.01% (v/v)) was added 1 h prior
to stimulation with IL-1. Medium was then removed and 10 Wl so-
dium arachidonate (10 mM) was added per sample, before centrifu-
gation at 6000Ug for 1 min. Total released 3H-labelled arachidonic
acid and its metabolites were measured by direct liquid scintillation
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counting of supernatants. Arachidonic acid was separated from PGE2
by organic extraction and TLC as described [16].
2.4. Northern and Western blot analysis
These were done as described previously [6]. A phosphorimager
(FLA2000, Fuji) was used for quantitation.
2.5. Construction of CP(32300/+30)pGL3b, a reporter gene plasmid
containing 2300 bp upstream of the human COX-2 promoter
High molecular-weight genomic DNA was puri¢ed from 108 human
peripheral blood mononuclear cells which had been prepared by Fi-
coll gradient centrifugation. The 2.3-kb upstream region of human
COX-2 promoter was ampli¢ed by 25 PCR cycles from 0.5 Wg ge-
nomic DNA using 50 pmol CP1, 50 pmol CP2, 250 WM dNTPs, and
5 U Taq/Pfu mix. The PCR fragment was then subcloned into pGL3b,
a commercial luciferase reporter plasmid lacking any eukaryotic or
viral promoter, at unique MluI/HindIII sites generated from the re-
spective primers. The cloned promoter region was sequenced commer-
cially. When compared with the three regions of corresponding se-
quence in GenBank it matched perfectly except for two possible
single-base discrepancies.
2.6. Transient transfection of HeLa cells with CP(32300/+30)pGL3b
Cells were seeded 24 h prior to transfection into 6-well plates. 1.45
Wg pBluescript (inert carrier), 0.5 Wg pGL3bWCP(32300/+30) and 0.05
Wg pCAT3 (a chloramphenicol acetyltransferase reporter plasmid
under the control of the SV40 promoter) were mixed with 10 Wl
‘Superfect’ reagent (Qiagen)/well and added to the cells for 2 h, fol-
lowing the manufacturer’s recommendations. The cells were then
washed, and harvested 24^48 h post-transfection, following appropri-
ate treatment. For harvesting, cells were lysed in 150 Wl lysis bu¡er (10
mM Tris-HCl, pH 8.0, 1 mM EDTA, 150 mM NaCl, and 0.65% (v/v)
Nonidet (NP-40)) per well and centrifuged at 12 000Ug for 2 min at
4‡C. Luciferase and CAT were assayed by standard methods. Luci-
ferase activities were normalised for any inter-sample transfection
variation with corresponding CAT activities.
2.7. Puri¢cation of c-Jun-N-terminal kinase (JNK) by anion exchange
chromatography
HeLa cells were stimulated with IL-1 (20 ng/ml, 15 min), collected
by scraping and lysed by passing through 23- and 25-gauge needles.
The lysate was cleared by centrifugation and chromatographed on a
Mono-Q column; elution was with a linear gradient of NaCl (0^0.5 M)
in 20 mM Tris-HCl bu¡er, pH 8.5, containing phosphatase inhibitors
[17]. Two peaks of JNK activity were detected by assay on GST-
c-Jun1ÿ135 [17,18]. These were tested for sensitivity to inhibition by
SB 203580 by pre-treating JNK for 15 min before assay.
2.8. Immunoprecipitation and assay of p38 MAPK or MAPKAPK-2
p38 MAPK was immunoprecipitated [4] and immunosorbates were
assayed in kinase bu¡er (30 Wl) containing 20 mM HEPES, pH 7.5, 20
mM Na-L-glycerophosphate, 200 mM NaCl, 2 mM DTT, 10 mM
MgCl2, 10 mM NaF, 0.1 mM Na-orthovanadate, 0.5 mM EDTA,
0.5 mM EGTA, 0.05% Brij35, 20 WM ATP, 0.03 mg/ml MAP-
KAPK-2 and 1.3 WCi/Wl [Q-32P]ATP. Samples were shaken for 20
min at room temperature before being boiled in SDS-PAGE sample
bu¡er for 5 min and subjected to SDS-PAGE. 32P incorporation into
MAPKAPK-2 was quanti¢ed in a phosphorimager. Immunoprecipi-
tation and assay of MAPKAPK-2 was performed in an identical
manner to that for p38 MAPK, except a sheep antiserum coupled
to protein G-agarose beads was used, and the immunosorbates were
assayed on hsp27 substrate.
2.9. Nuclear run-on assays
These were based on the method described in [19]. 4U175-cm2
£asks of HeLa cells were used for each treatment. Cells were scraped
into phosphate-bu¡ered saline, centrifuged (500Ug for 5 min) and
lysed by resuspension (250 Wl/£ask) in nuclear extraction bu¡er
(0.14 M NaCl, 1.5 mM MgCl2, 10 mM Tris-HCl, pH 8.6, 0.5%
(v/v) NP-40, 1 mM DTT, 40 U/ml ‘RNasin’). Nuclei were centrifuged
(500Ug for 5 min) washed twice and stored in liquid nitrogen as
described [19]. Run-on assays and RNA extraction were performed
as described [19]. Equivalent amounts of radiolabelled RNA (usually
about 5U106 cpm/sample) were added to 2 ml hybridisation mixture
(50% (v/v) formamide, 5U SSPE, 5% (v/v) Denhardt’s solution, 0.1%
(w/v) SDS, 0.1 mg/ml salmon sperm DNA) and hybridised to slot
blots for 72 h at 42‡C. Slot blots contained cDNAs of interest in
pBluescript (human COX-2, human L-actin). The plasmid DNA
(10 Wg/slot) had been linearised, denatured, and UV-crosslinked to
Hybond N as described [19]. Wash steps were also performed as
described [19] and the blots were visualised by autoradiography,
and quanti¢ed using a phosphorimager.
3. Results
3.1. SB 203580 inhibits PGE2 , but not arachidonate, release
from IL-1-stimulated HeLa cells
HeLa cells were metabolically labelled with [5,6,7,8,9,11,
12,14,15-3H](N)]-arachidonic acid and pre-treated with SB
203580 1 h prior to stimulation with IL-1 for 2 h in the
continuing presence of the inhibitor. Medium was removed
and its 3H content determined (Fig. 1A). Increasing doses of
SB 203580 inhibited the release of [3H]arachidonate metabo-
lites and separation of these by TLC revealed that they mainly
comprised PGE2. This was consistent with our earlier ¢ndings
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Fig. 1. SB 203580 inhibits PGE2, but not arachidonic acid release
from IL-1-stimulated HeLa cells. HeLa cells were metabolically la-
belled with [5,6,7,8,9,11,12,14,15-3H](N)]arachidonic acid (AA) be-
fore washing. A: Varying concentrations of SB 203580 were added
1 h prior to stimulation with IL-1 (20 ng/ml) for 2 h. Culture me-
dium was then removed and its 3H content measured directly by
liquid scintillation counting. B: Cells were pre-treated for 1 h with
1 WM SB 203580 before stimulation with IL-1 for 45 min.
[3H]Arachidonic acid was extracted and separated from [3H]PGE2
by TLC. Representative experiments are shown. Data points are
mean þ S.D. of triplicate determinations.
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in human ¢broblasts where IL-1-stimulated PGE2 production
(measured by radioimmunoassay) was inhibited by SB 203580
with an IC50 V0.1 WM [6]. It is thought that IL-1 activates
cytoplasmic phospholipase A2 (cPLA2) in cells in order to
provide arachidonate as substrate for prostaglandin synthesis,
and that activation may involve phosphorylation by MAP
kinases. We therefore investigated the early increase in arach-
idonate release caused by IL-1, before signi¢cant amounts of
COX-2 are induced. Medium was harvested after 45 min of
stimulation of HeLa cells with IL-1. It was extracted and
subjected to TLC as described in Section 2 and the radioac-
tivity in the arachidonic acid band was measured (Fig. 1B).
IL-1 approximately doubled the release of arachidonate, but
this was una¡ected by the p38 MAPK inhibitor. We con-
cluded that p38 MAPK was not involved in the early mobi-
lisation of arachidonic acid from membranes.
3.2. SB 203580 inhibits induction of COX-2 protein and mRNA
Having established that the inhibitor was acting at a level
between arachidonate and PGE2 release, we examined its ef-
fect on induction of COX-2. SB 203580 inhibited induction of
COX-2 protein (Fig. 2A) and mRNA (Fig. 2B) by IL-1 with
an IC50 in the range 0.1^0.5 WM, consistent with our obser-
vations in ¢broblasts [6].
3.3. JNK activity in IL-1-stimulated HeLa cells is una¡ected
by 0.1 WM SB 203580
Since WM concentrations of the inhibitor have recently been
shown to inhibit certain JNK isoforms [20,21] we separated
IL-1-activated JNKs from HeLa cells by anion exchange
chromatography as described in Section 2. Two main peaks
of JNK activity were identi¢ed corresponding to the ‘short’
(eluting earlier) and ‘long’ forms [17]. The peaks were assayed
in the presence of increasing doses of SB 203580: The early
peak was una¡ected by 1 WM, and was inhibited 15% at 5 WM
(data not shown). The later peak was inhibited 10% at 1 WM
and 40% at 5 WM (data not shown). Neither peak was a¡ected
by 0.1 WM inhibitor. We concluded that e¡ects of SB 203580
observed in the 0.1^1-WM range were unlikely to be due to
e¡ects on JNKs.
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Fig. 3. The e¡ects of SB 203580 upon IL-1-stimulated COX-2 tran-
scription. A: HeLa cells were transiently-transfected with
CP(32300/+30)pGL3b, a luciferase reporter gene plasmid containing
2300 bp upstream of the human COX-2. Cells were pre-treated with
either 1 WM SB 203580 or DMSO vehicle for 1 h prior to stimula-
tion with IL-1 (20 ng/ml) for the times indicated. Cells were har-
vested (30 h post-transfection) and assayed for luciferase. A repre-
sentative experiment of three is shown; data points are mean
normalised luciferase activities þ S.D. of triplicate determinations. B:
HeLa cells were treated for 1 h with either 1 WM SB 203580 or
DMSO vehicle and were stimulated with IL-1 (20 ng/ml) for 30
min. Nuclei were then prepared and 5U107 from each treatment
used in run-on assays in the presence of [K-32P]UTP. The nascent
mRNA transcripts were then extracted and hybridised to slot-blots
of pBluescript (pBS) which contained cDNAs for human COX-2 or
L-actin. The slot-blots were then washed and autoradiographed.
Quantitation was achieved using a phosphorimager (C).
Fig. 2. SB 203580 inhibits IL-1-induced COX-2 expression in HeLa
cells. HeLa cells were pre-treated for 1 h with varying concentra-
tions of SB 203580 prior to stimulation with IL-1 (20 ng/ml). A:
Western blot of COX-2 in detergent-lysed cells following 6 h stimu-
lation with IL-1. Antigen detection was by enhanced chemilumines-
cence. B: Northern blots of COX-2 mRNA following 4 h stimula-
tion with IL-1. Total cellular RNA was prepared and 5 Wg/lane
blotted for COX-2 and GAPDH mRNA expression with 32P-la-
belled cDNA probes and visualised by autoradiography.
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3.4. IL-1-induced COX-2 transcription is independent of p38
MAPK
The e¡ect of the inhibitor upon COX-2 transcription in-
duced by IL-1 was investigated in two ways.
Firstly we used a reporter gene assay. A luciferase reporter
plasmid containing 2.3 kb upstream of the human COX-2
coding region was made as described in Section 2. This was
transiently transfected into HeLa cells. IL-1 weakly stimulated
(about 2-fold at 4 h and 8 h) the activity of the reporter gene
(Fig. 3A), whilst PMA treatment caused up to 15-fold activa-
tion (data not shown). Pre-treatment with 1 WM SB 203580
resulted in partial inhibition (20%) of the IL-1-stimulated lu-
ciferase expression (Fig. 3A). Similar weak inhibition was seen
in other experiments.
The results of the reporter gene assays suggested that the
increase in the rate of COX-2 transcription caused by IL-1
was relatively small, and that it was only weakly regulated by
p38 MAPK. We therefore investigated transcription of COX-
2 more directly by nuclear run-on assay. In two separate ex-
periments, IL-1-stimulated COX-2 transcription in HeLa cells
was activated about 2-fold (relative to L-actin), and pre-treat-
ment with 1 WM SB 203580 had no signi¢cant e¡ect (Fig. 3B
and C).
3.5. SB 203580 rapidly destabilises COX-2 mRNA in
IL-1-stimulated HeLa cells
The possible e¡ect of the p38 MAPK inhibitor upon COX-
2 transcription did not account for the strong inhibition of
mRNA induction. We therefore investigated the e¡ect of the
inhibitor upon the stability of COX-2 mRNA. HeLa cells
were ¢rst stimulated with IL-1 for 2 h to allow accumulation
of COX-2 mRNA. Following this actinomycin D was added
to the cells to block any further transcription, with or without
1 WM SB 203580 (Fig. 4). In the absence of the inhibitor the
mRNA decayed partially (40%) in the ¢rst 30 min, but then
remained constant. However, the presence of SB 203580
strongly enhanced the decay (about 80% by 1 h). Thus in
the absence of p38 MAPK activity the COX-2 mRNA became
unstable.
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Fig. 5. Time course of p38MAPK activation (A) and inhibition of
MAPKAPK-2 activation by SB 203580 (B). A: HeLa cells were
stimulated with IL-1 for indicated times. Cells were washed and
lysed. Lysates were treated with antiserum to p38 MAPK, and im-
munoprecipitates were assayed on recombinant MAPKAPK-2 as de-
scribed in Section 2. 32P incorporation into MAPKAPK-2 was
quanti¢ed in a phosphorimager after separation of products by
SDS-PAGE. A representative experiment of 3 is shown. B: Indi-
cated doses of SB 203580 were added to HeLa cells simultaneously
with IL-1 (20 Wg/ml) (L H panel) or to cells which had been pre-
treated with IL-1 for 1.75 h (R H panel). After 15 min further incu-
bation cells were washed, lysed and MAPKAPK-2 was immunopre-
cipitated and assayed on hsp 27 as described in Section 2. 32P
incorporation into hsp 27 was quanti¢ed in a phosphorimager after
SDS-PAGE. SB 203580 (1 WM) had no e¡ect on MAPKAPK-2 ac-
tivity when added directly to the kinase assay (data not shown).
Fig. 4. SB 203580 rapidly destabilises COX-2 mRNA in HeLa cells.
HeLa cells were stimulated with IL-1 for 2 h. Actinomycin D
(Act.D, 1 Wg/ml) with either DMSO vehicle or with SB 203580
(1 WM) was added to the cells for the times indicated. Total RNA
was prepared and Northern blotted (6 Wg/lane) for COX-2 and
GAPDH mRNAs with 32P-labelled cDNA probes which were vis-
ualised by autoradiography and quanti¢ed in a phosphorimager. A
shows the autoradiograph of a representative experiment. B shows
means þ S.D. derived from two independent experiments.
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3.6. Near to basal levels of p38 MAPK regulate COX-2 mRNA
stability
In the experiment shown in Fig. 4, SB 203580 was added 2 h
following IL-1 stimulation. We examined the time-course of
p38 MAPK activation by immunoprecipitation kinase assay
(Fig. 5A). IL-1 activation of p38 MAPK was strong at 15 min
as expected. It returned towards basal level by 1 h, but re-
mained 3-fold elevated for up to 4 h. To investigate whether
or not this relatively low level of p38 MAPK at 2 h was
biologically signi¢cant, we measured the e¡ect of adding the
inhibitor upon the activity of the best characterised substrate
of p38 MAPK, MAPKAPK-2. Fig. 5B shows that the pres-
ence of SB 203850 at the time of maximum p38 MAPK ac-
tivity (L H panel) and after return of p38 activity towards the
basal level at 2 h (R H panel) inhibited p38 MAPK in the cells
as judged by the reduction in MAPKAPK-2 activity at either
time point. SB 203580 (1 WM) has no e¡ect on the activity of
MAPKAPK-2 itself when added directly to the kinase assay.
We concluded that it is the continuing p38 MAPK activity
that is required to stabilise the COX-2 mRNA, rather than the
transient large increase in the initial activity caused by IL-1
stimulation of the cells.
4. Discussion
The two main conclusions to be drawn from the experi-
ments were ¢rstly that, as in ¢broblasts, p38 MAPK activity
was needed for IL-1 induction of prostaglandin synthesis in
HeLa cells, and secondly, that the kinase is needed to stabilise
COX-2 mRNA. Hitherto p38 MAPK has been thought to
regulate transcription factors and the actin cytoskeleton and
our ¢ndings suggest a new function for this kinase pathway.
We ¢rst established that stimulation of synthesis of PGE2
and COX-2 by IL-1 was inhibited by SB 203580 in HeLa cells
in a manner similar to that seen in ¢broblasts [6].
We investigated whether SB 203580 had any e¡ect on IL-1-
stimulated arachidonate release. This is thought to be medi-
ated by cPLA2 which has been proposed as a substrate for
p38 MAPK [22]. Our ¢nding that the inhibitor at 1 WM had
no e¡ect on arachidonate release was consistent with our ear-
lier observations in activated platelets [4].
The speci¢city of the inhibitor has recently been questioned.
It was originally described as highly speci¢c for p38 MAPK
[23]. However, certain JNK isoforms (JNK2L and JNK1L) are
signi¢cantly inhibited by it at 1 WM [20,21]. We therefore
checked the susceptibility of HeLa JNKs to the inhibitor.
The second chromatographic peak of JNK activity from IL-
1-treated HeLa cells was inhibited 10% by 1 WM SB 203580.
However, since signi¢cant inhibition of COX-2 expression
(and PGE2 production) was observed at 0.1 WM SB 203580,
our results cannot be attributed to inhibition of JNK. Fur-
thermore the initial evidence obtained with the inhibitor that
p38 MAPK is involved in COX-2 expression has been sup-
ported by experiments in which activation of the pathway (by
transfection of upstream kinases) caused COX-2 expression
[24].
In order to investigate the mechanism by which the p38
MAPK inhibitor prevented COX-2 expression we ¢rst inves-
tigated transcription. There are several reports of transcrip-
tional activation of COX-2 by IL-1. Activation ranged from
8-fold in A549 cells [25] to 15-fold in endothelial cells [26]
when measured by nuclear run-on. Assays of IL-1-stimulated
transcription using a reporter gene linked to the COX-2 pro-
moter showed about a 2-fold increase in endometrial cells [27]
and were unsuccessful in A549 cells [25]. Since we measured a
relatively weak activation of a reporter gene in HeLa cells we
also measured transcription by nuclear run-on assay. The re-
sults of this were very similar to the reporter gene assays. The
2-fold increase in transcription caused by IL-1 was not sig-
ni¢cantly a¡ected by SB 203580 treatment in nuclear run-on
assay, and the e¡ect in the reporter gene assay was minimal.
The major e¡ect of SB 203580 was to destabilise rapidly
COX-2 mRNA. The fact that the inhibitor was e¡ective in the
presence of actinomycin D excluded any possible contribution
of p38 MAPK to transcription and showed that the destabi-
lisation occurs through modulation of extant factors. Dexa-
methasone has also been shown to destabilise COX-2 mRNA
in IL-1-stimulated endothelial cells, but this required on-going
transcription and was not seen in the presence of actinomycin
D [28].
The 3P-UTR has been implicated in the regulation of COX-
2 mRNA stability [29,30], but it remains to be seen whether
p38 MAPK regulates COX-2 expression through this mecha-
nism, and by which downstream targets.
In conclusion we suggest that a novel function for p38
MAPK may be to regulate mRNA stability, and it will be
interesting to see if other in£ammatory response genes whose
expression is regulated by this kinase are controlled through a
similar mechanism.
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